TRLV Stock Forecast & Price Target

Trulieve Cannabis is supported by a validated medical-use thesis, as the DEA’s first batch of registrations included its state-licensed dispensaries, confirming the pathway created by Schedule III reclassification and the potential for relief from 280E. Its vertically integrated platform looks scaled and efficient, with a 750K sq. ft. highly automated cultivation facility, a 162-store Florida footprint, 2Q26 revenue of $271M, and EBITDA of $98M, while 3Q26 revenue guidance of $222M remains above consensus. The bullish view is further reinforced by market-leading Florida execution, accelerating growth in Georgia and Pennsylvania, and meaningful upside from Texas, hemp restrictions, and other federal catalysts that are not reflected in estimates.

Trulieve Cannabis is exposed to a difficult risk profile that combines company-specific execution challenges with broader cannabis-industry headwinds, including delayed regulatory approvals that could slow expansion and impair growth visibility. Its heavy operational concentration in Florida, with additional exposure in Arizona and Pennsylvania, increases reliance on a limited set of markets while state-level legislative and regulatory changes can quickly alter access, compliance costs, and revenue potential. Competitive pricing pressure further threatens margins in a capital-intensive, vertically integrated model, making it harder to translate its multi-state footprint into durable profitability.